In one study, 161 stage II–III high-risk resected melanoma patients treated with adjuvant bevacizumab versus (vs.)placebo within the AVAST-M clinical trial were studied with ddPCR to detect BRAF and NRAS common mutations in plasma [82] (Table 3). The gene discussed is BRAF; the disease is melanoma.